Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5562 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 35 36 37 ... 54 55 56  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Zytoprotec–Baxter: investment, 201301 financing €2m from new investor Baxter Ventures 2013-01-29
Advanova–High-Tech Gründerfonds: investment, 201301 1st financing round HTGF + BayernKapital + consortium of business angels 2013-01-28
Advanova–SEVERAL: investment, 201301 1st financing round HTGF + BayernKapital + consortium of business angels 2013-01-28
AstraZeneca–Max Planck: drug discovery services, 201301–201412 collab screening of 250k compounds from AZ against targets from LDC partners at LDC 2013-01-25
Cytos Biotechnology–SA Noonan Communications: public relations, 201301 service existent 2013-01-23
DPPN–Germany (govt): grant, 2001301–201712 support €35m for 5 years from BMBF 2013-01-23
Lophius–SEVERAL: investment, 201301 financing round €4m VRD GmbH + WIC GmbH + S-Refit + HTGF + Bayern Kapital + 2 business angels 2013-01-22
Applied Microarrays–Schott: microarray slides, 201301– distribution of Nexterion products in US + Canada by AMI 2013-01-21
Ayoxxa–National Univ Singapore: protein micorarray technology, 201301– collab r+d IEBA technology with Dept of Bioengineering at NUS 2013-01-21
Ayoxxa–SEVERAL: investment, 201301 financing round Series A 2nd Closing €0.4m incl new investor KfW Bankengruppe 2013-01-21
Global Alliance of Leading Drug Discovery & Development Centres–Max Planck: drug discovery, 201301– LDC is founding member 2013-01-21
Markes International–Schauenburg: investment, 201301 acquisition of majority share by Schauenburg International 2013-01-16
Paladin Labs–Apeiron: APN311, 201301– license excl €na to market + sell APN311 in Canada + Sub-Saharan Africa incl South Africa 2013-01-16
Leibniz-Gemeinschaft–Wiley: investment, 201301 acquisition of the assets of FIZ Chemie from German govt + Berlin govt et al 2013-01-15
Boehringer–Horizon Discovery: drug discovery services, 201301– collab 5 years €na supply of services using X-MAN + GENESIS technologies in oncology 2013-01-14
pH (IT)–TÜV Süd: investment, 201301 aquisition 100% of pH s.r.l. 2013-01-11
Evotec–Yale Univ: drug discovery, 201301– strategic partnership to combine Evotec drug discovery infrastructure with Yale research 2013-01-09
Spinomix–Debiopharm: investment, 201301 financing round Series A $3m led by Debiopharm 2013-01-09
Spinomix–SEVERAL: investment, 201301 financing round Series A $3m led by Debiopharm 2013-01-09
STATegra project–Biomax: bioinformatics, 201301– Biomax Informatics AG is project member 2013-01-09
Prophyta–Bayer: investment, 201301 acquisition €na by Bayer CropScience 2013-01-08
AstraZeneca–Evotec: antidiabetics, 201301– collab + license agreem expansion + extension until end of 2013 with MedImmune 2013-01-07
Drug Response Dx–High-Tech Gründerfonds: investment, 201301 1st financing round with Qiagen + HTGF 2013-01-07
Drug Response Dx–Qiagen: investment, 201301 1st financing round with Qiagen + High-Tech Gründerfonds 2013-01-07
Drug Response Dx–SEVERAL: investment, 201301 1st financing round with Qiagen + High-Tech Gründerfonds 2013-01-07
GSK–Priaxon: drug discovery services, 201301– supply service €na to identify + develop small molecule modulators of protein-protein-interactions 2013-01-07
ISA Pharmaceuticals–Akampion: public relations, 201301 service existent 2013-01-07
Qiagen–Drug Response Dx: genomic biomarker, 201301– license option ww rights to biomarkers for companion tests for TNA-alpha inhibitors for RA 2013-01-07
Qiagen–France (govt): genomic biomarker, 201301– license excl ww mutations of HSP110 gene for PDx in colorectal cancer from Inserm 2013-01-07
Qiagen–Insight Genetics: genomic biomarker, 201301– license excl ww for genetic test incl 3 new markers for PDx in lung cancer 2013-01-07
Shire–Ethris: RNA-based therapeutics, 201301– collab €na developm + commercialisation of RNA therapeutics using SNIM technology 2013-01-07
Bruker Corp–Erasmus Univ: clinical diagnostics, 201301– license excl for MALDI-TOF-based beta-lactamase testing from EMC 2013-01-03
CCS Cell Culture Service–Evotec: investment, 201301 acquisition 100% for €1.15m in cash upfront + 1 year-milestone of €1.05 in cash 2013-01-03
Cevec–Deutsche Stiftung Impfstoffforschung: vaccine technology, 201301– license excl to CMV dense body techn for developm of CMV vaccine from VPM 2013-01-03
Apeiron–Evotec: cancer immunotherapy, 201301– collab €na development of lead compounds 2013-01-02
ABF–Genedata: bioinformatics, 2013– supply use of Genedata Selector by AB Enzymes for strain genome data management 2013-01-01
Apceth–Germany (govt): grant, 201301–201503 2nd of 2 funding phases within m4 Cluster from BMBF w total €4.7m for both phases 2013-01-01
BioNTech–4SC: drug discovery services, 201301–201512 collab service identification + optimisation of small-molecular cancer drugs by 4SC Discovery 2013-01-01
BioNTech–MAB Discovery: antibody technology, 2013– collab mAb generation using technology of MAB Discovery 2013-01-01
Boehringer–Blackfield: cancer genomics, 2013– service application of genomics technology + computational biology for cancer drug developm 2013-01-01
Boehringer–Qiagen: molecular companion diagnostics, 2013 collab existent incl therascreen EGRF RGQ PCR Kit for Giotrif 2013-01-01
Hookipa–College Group: public relations, 201301– service Hookipa new customer of College Hill Life Sciences in early 2013 2013-01-01
Innovative Medicines Initiative–Bruker Corp: antibiotics, 201301–201712 project partner Bruker Daltonik GmbH in €29.3m TRANSLOCATION project of IMI 2013-01-01
Innovative Medicines Initiative–EU (govt): grant, 201301–201712 funding support €16m for TRANSLOCATION project by IMI total project cost €29.3m 2013-01-01
Innovative Medicines Initiative–European ScreeningPort: antibiotics, 201301–201712 partner in €29.3m TRANSLOCATION project of IMI 2013-01-01
Innovative Medicines Initiative–Ionovation: antibiotics, 201301–201712 project partner Ionovation GmbH in €29.3m TRANSLOCATION project of IMI 2013-01-01
Innovative Medicines Initiative–Jacobs Univ: antibiotics, 201301–201712 project coordinator in €29.3m TRANSLOCATION project of IMI 2013-01-01
Jacobs Univ–Bremen (govt): grant, 2013–2017 funding €15m over 5 years by Federal State of Bremen 2013-01-01
JnJ–Blackfield: cancer genomics, 2013– service application of genomics technology + computational biology for cancer drug developm 2013-01-01
Kaiser Optical Systems–Endress+Hauser: investment, 2013 acquisition by Endress+Hauser 2013-01-01
Merck (DE)–Blackfield: cancer genomics, 2013– service application of genomics technology + computational biology for cancer drug developm 2013-01-01
Omnilab (DE)–Bruker Corp: laboratory consumables, 201301– distribution of Bruker GC + MS consumables in Germany by Omnilab 2013-01-01
Panatecs–HWI Analytik: analytical services, 201301– strategic alliance offering of complementary portfolio of services 2013-01-01
Roche–Wilex: ADC technology, 2013–201508 collab ATACs with Heidelberg Pharma TERMINATED by Roche 8/15 2013-01-01
Siemens–CellaVision: cell analysis technology, 201301– distribution ww of CellaVision products by Siemens Healthcare Diagnostics 2013-01-01
Sigma-Aldrich–Olink: research reagents, 2013– distribution of Duolink reagents by Sigma-Aldrich 2013-01-01
Strüngmann Group–College Group: public relations, 201301– service AiCuris new customer of College Hill Life Sciences in early 2013 2013-01-01
SIRS-Lab–NONE: investment, 201212–201305 bankruptcy filed at Local Court Gera 8 IN 641/12 2012-12-31
Epigenomics–SEVERAL: investment, 201212–201301 capital increase just under €5m gross proceeds to avoid prospectus publication 2012-12-20
NYSE Euronext–IntercontinentalExchange: investment, 201212–201311 acquisition $11b in cash + shares 2012-12-20
Yuhan–Cevec: CAP technology, 201212– license to use CAP + CAP-T cell expression systems therapeutic protein developm + production 2012-12-20
Sartorius–Lonza: cell culture media, 201212– collab €na global sales + marketing of media + buffers by SSB which takes over Lonza medial sales team 2012-12-19
Poxel–MC Services: public relations, 201212 service existent for Poxel SA 2012-12-18
Sartorius–MKS Instruments: cheminformatics, 201212– global marketing + distribution of Umetrics’ s/w for biopharma developm + manufacturing by SSB 2012-12-18
BioNTech–4SC: TLR agonists, 201212– excl ww research + license agreem as cancer immunotherapy €2.5m + milestones + royalties 2012-12-17
Debiopharm–Roche: cancer drug, 201212– license ww excl from Chugai to develop + commercialise FF284 (Debio 1347) upfront fee + milestones + royalties 2012-12-17
JnJ–Evotec: NMDA receptor NR2B subtype selective antagonists, 201212– license excl ww compound portfolio to treat depression 2012-12-17
Intercell–Vivalis: investment, 201212–201305 merger into Valneva SE with former Vivalis owners holding 55% of shares 2012-12-16
MorphoSys–Bio-Rad: investment, 201212–201301 acquisition of AbD Serotec division for €53m in cash by Bio-Rad incl non-excl license to HuCAL 2012-12-16
Astellas–Basilea: antifungal, 201212– collab existent joint development of isavuconazole 2012-12-14
Auven Therapeutics–College Group: public relations, 201303 service existent by College Hill 2012-12-13
Cube Biotech–Creathor Venture: investment, 201212 financing round Series A led by Creathor Venture Fund III joined by local business angels 2012-12-13
Cube Biotech–SEVERAL: investment, 201212 financing round Series A led by Creathor Venture Fund III joined by local business angels 2012-12-13
Prosensa–College Group: public relations, 201212 service existent by College Hill 2012-12-13
Biocartis–SEVERAL: investment, 201212 financing round Series D €34.5m lead investor PMV using TINA fund 2012-12-12
Anagnostics–Scienion: print/spotting technology, 201211 supply use of sciFlexarrayer for production of hybcell tests incl new integrated sepsis test 2012-12-11
Biognosys–SEVERAL: investment, 201212 intermediate financing round closed 2012-12-07
Biobase–Univ Southern California: genomic s/w, 201212– distribution rights ww excl for ANNOVAR s/w from USC + CHOP 2012-12-05
PlasmidFactory–Sirion Biotech: gene delivery technology, 201212– collab pronotion of AAV vectors for preclinical ersearch 2012-12-04
Allergopharma–Merck (DE): investment, 201212 acquisition of all remaining interests by Merck who has been majority shareholder since founding 2012-12-01
Imperial College–Bruker Corp: analytical technology, 201211– Bruker is 1 of the 6 partners of newly planned MRC-NIHR Phenome Centre at Imperial 2012-11-30
Techno X–Analytik Jena: investment, 201211 acquisition of 20.05% stake in Techno X + extension of collaboration 2012-11-30
COBIK–ACIB: industrial biotechnology, 201211– collab developm of environmentally friendly processes + technologies 2012-11-28
Probiodrug–Evotec: drug development services, 201211– collab assay developm for prec-clinical + clinical developm of QC inhibitors for Alzheimer’s 2012-11-28
Roche–MIT: drug development, 201211– collab €na multi-year drug repositiong of 300 Roche compounds by Broad Institute 2012-11-28
BRAIN–SEVERAL: investment, 201211 financing round €60m led by MP Beteiligungs-GmbH + MIG Fonds 2012-11-27
Univ Bochum–DFG (DE): grant, 201211– DFG grant €7.2m for 3rd + final phase 3.5y of SFB 642 2012-11-27
Lanthio Pharma–MorphoSys: investment, 201211 financing round Series A 1st closing totalling €4.8m incl co-investor MorphoSys AG 2012-11-26
Lanthio Pharma–Several: investment, 201211 financing round Series A 1st closing €4.8m led by BioGeneration Ventures + INKEF Capital 2012-11-26
MorphoSys–Lanthio Pharma: LanthioPep technology, 201211– collab €na alliance to jointly develop LanthioPep technology 2012-11-26
Radimetrics–Bayer: investment, 201211 acquisition €na by Bayer HealthCare 2012-11-26
MVZ Dortmund–Orexo: IRIS analyser, 201211 supply existent 2012-11-23
InnoCyte–Baden-Württemberg (govt): investment, 201211 1st financing round totalling high 6-digit€ amount incl investor Seedfonds BW 2012-11-22
InnoCyte–Fraunhofer: investment, 201211 1st financing round totalling high 6-digit€ amount incl investor Fraunhofer Venture 2012-11-22
InnoCyte–High-Tech Gründerfonds: investment, 201211 1st financing round totalling high 6-digit€ amount incl investor HTGF 2012-11-22
InnoCyte–SEVERAL: investment, 201211 1st financing round high 6-digit€ amount from HTGF + Seedfonds BW + Fraunhofer Venture 2012-11-22
Evolva–Fluxome: food ingredients, 201211– acquisition of certain assets of Fluxome Sciences A/S which is in reconstruction ANNOUNCED 2012-11-21
Pronova BioPharma–BASF: investment, 201211–201301 public cash offer NOK4.996b=€684m NOK13.5/share by BASF AS 2012-11-21
Sekisui–ViruSure: quality control diagnostics, 201211– marketing of ViruSure services for virus + prion safety in Japan by Sekisui Medical 2012-11-21
BioCat GmbH–ALPCO Diagnostics: ELISA kits, 201211– distribution excl of ALPCO products in Germany by BioCat GmbH 2012-11-19
next pagenext page 1 2 3 ... 35 36 37 ... 54 55 56  next pagenext page



Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top